Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) have earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.4167.
ADPT has been the subject of several recent research reports. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Morgan Stanley boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th.
Check Out Our Latest Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Price Performance
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. During the same period in the prior year, the company posted ($0.17) earnings per share. The business’s revenue was up 21.5% on a year-over-year basis. As a group, analysts forecast that Adaptive Biotechnologies will post -0.4 EPS for the current year.
Insider Buying and Selling
In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 321,324 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the transaction, the chief executive officer directly owned 2,180,518 shares in the company, valued at $54,687,391.44. The trade was a 12.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the transaction, the insider directly owned 221,278 shares of the company’s stock, valued at $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,062,325 shares of company stock valued at $46,659,069 over the last 90 days. 5.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after acquiring an additional 2,914 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Adaptive Biotechnologies during the first quarter worth about $93,000. New York State Common Retirement Fund increased its holdings in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after acquiring an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after acquiring an additional 333,379 shares during the period. 99.17% of the stock is currently owned by institutional investors.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Stories
- Five stocks we like better than Adaptive Biotechnologies
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
